MONALEESA-3 is a phase III randomized, double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for treating postmenopausal women and men with HR+/HER2− advanced BC who have received no or only one line of ET for advanced BC [38]. Here, ERBB2 is linked to breast cancer.